Endocrine Abstracts

Introduction

Growth retardation (GR) is a frequent complaint in pediatrics. A clear and rapid diagnostic process is essential in order to improve the prognosis for height. The aim of our study was to review the epidemiological, clinical and etiological aspects of GR and to assess the height gain particularly after treatment for Growth hormone (GH) deficiency.

Methodology

This is a retrospective study of 27 consulting patients for GR at the endocrinology department of the Military Hospital of Tunis between January 2000 and December 2019.

Results

Our population was predominately male (sex ratio = 2). The mean chronological age (CA) at the time of diagnosis was 13.8 ± 3.8 years. The mean linear growth retardation was -3.02 ± 0.73 standard derivation (S.D.). Fifteen patients (62%) had severe GR (≤-3S.D.). The mean bone age (BA) was 10.23 ± 2.49 years, with a mean delay (CA-BA) of 3.5 ± 2.06 years. Dysmorphia was found in 11% of cases. Delayed puberty was associated in 62% of cases. GH deficiency was found in 56% of cases; 71% had total GH deficiency and 29% had partial GH deficiency. They were treated with somatotropin. The height gain after treatment for GH deficiency was 20.62 ± 14.32 cm. The other causes were celiac disease (8%), constitutional GR (8%), genetic and malformative diseases (14%), 1 case of type 1 diabetes, 1 case of peripheral hypothyroidism and 1 case of GR secondary to a small size from birth.

Conclusion

Monitoring growth should be systematic and regular in all children. By an early diagnosis of GR, serious diseases can be detected and an appropriate treatment can be started at an early stage.